D. E. Shaw & Co., Inc. Mirati Therapeutics, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $1.41 Million - $2.81 Million	-18,600 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $1.43 Million - $2.06 Million	-10,800 Reduced 36.73%	18,600 $2.73 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $2.64 Million - $3.55 Million	-20,000 Reduced 40.49%	29,400 $5.2 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $4.97 Million - $7.38 Million	30,700 Added 164.17%	49,400 $10.9 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $985,362 - $1.46 Million	8,700 Added 87.0%	18,700 $3.11 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $594,900 - $1.05 Million	10,000 New	10,000 $1.03 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.